UCB's CEO: China Now Sources 1 in 4 of the World's New Drugs, and the "China for China" Mindset Is Over

BEIJING — UCB chief executive Jean-Christophe Tellier told China Daily in an interview published on June 26, 2026 that China has moved from manufacturing to clinical-trial expertise, and is now becoming a source of drug discovery for the rest of the world. The remarks came during a Beijing visit earlier this month that brought nearly UCB's entire global executive committee to mark the company's 30th anniversary in China — and to sign a new agreement establishing the UCB China Integrated Operation Centre in the Suzhou Industrial Park in Jiangsu province.

"Bringing the executive committee with me — and almost everyone came — was a symbol of China's importance," Tellier said. "When people saw all of us here, they realised that when we said China is important for us, it's a reality."

The single sentence that reframes the conversation

Tellier's most quoted line from the interview is direct and unfashionable for a multinational executive: "China has moved from manufacturing to clinical trial expertise, and is now becoming a source of discovery and innovation for the rest of the world." It matters because it comes from a CEO whose company has no obvious reason to flatter Beijing. UCB is Belgian, founded in 1928, with deep roots in European pharmaceutical conventions and a portfolio historically anchored to neurology and immunology assets developed in Brussels and Slough.

The older framing — China as a place where Western companies bring finished products to sell — is what Tellier is publicly retiring. The newer framing — China as a place where new medicines are born and where the West should expect to license them — is what he is publicly endorsing.

UCB has some recent standing to make the case. On June 4, 2026, the company signed an agreement with the Suzhou Industrial Park in Jiangsu to establish the UCB China Integrated Operation Centre. The stated mission: end-to-end commercialisation, distribution, and supply capabilities for the Chinese market. The implied mission, as Tellier puts it: "There is an element of investing to strengthen our supply chain — something that in our industry is becoming more local and less global. The era of supplying the entire world from a single location is over."

This is not a small reorganisation. For an innovative-drug company, localising the supply chain means building fill-finish, cold-chain distribution, and regulatory-affairs infrastructure inside China — the kind of investment that companies typically only make when they expect a multi-decade presence and a meaningful share of regional sales.

The numbers behind the shift

Tellier's most concrete quantitative claim is the "1 in 4" figure: roughly one in four new drugs discovered globally now comes from China. He expected that ratio to rise toward two in four in the near future.

This is not a number UCB invented. The same ratio has been appearing in industry analyses from the past 18 months, with the underlying denominator shifting as more Chinese-discovered candidates progress through FDA and EMA reviews. What UCB adds to the data point is a corporate strategy statement: "When you discover new medicines, they cannot be just for China — patients are everywhere. Science is global. Progress is global."

On the NMPA side, the regulatory throughput is now visible in year-over-year approval counts. The NMPA approved 76 innovative drugs in 2025 — a record — up sharply from the 48 approved in 2024. So far in 2026, 19 innovative drugs have been approved, 15 of which originated with Chinese manufacturers. That ratio is striking: nearly 80% of new innovative-drug approvals in China in 2026 come from domestic labs, not Western pharma's local affiliates.

For an international patient considering China as a treatment destination, the 15-out-of-19 ratio translates into a clinical picture that is increasingly shaped by therapies whose Phase 1, Phase 2, and registration Phase 3 data were all generated in Chinese hospitals. That has implications for the patient population in which a drug was first tested, the biomarker frequencies that drive efficacy, and the dose-management experience that clinicians have accumulated — all of which are real, measurable differences between "approved in China" and "approved globally with a China-only label."

How China got here: the 2020 Provisions for Drug Registration

Tellier is unusually specific about which Chinese policy lever accelerated the shift. He points to the fast-track review pathways launched in the Provisions for Drug Registration issued in 2020. These pathways — breakthrough therapy designation, conditional approval, priority review — were later folded into the new regulations of China's Drug Administration Law, which took effect in May 2025, strengthening the legal basis for expedited drug approval.

"The speed by which China is now doing approvals is ahead of everybody else," Tellier said. "There is really this willingness, engagement and commitment across the healthcare ecosystem to deliver innovative solutions as quickly as possible, which is really remarkable."

From an international-patient perspective, the regulatory speed matters because the Chinese approval-to-access window is now often shorter than the equivalent window in the United States or Europe. For a drug first developed in China — a Claudin18.2 CAR-T for gastric cancer, a LILRB4 bispecific for AML, an iPSC therapy for Parkinson's — the path from "first-in-human data published" to "commercial access in Shanghai" can now be 18 to 30 months. The corresponding FDA timeline is often 36 to 60 months for the same asset.

What UCB is doing specifically — 14 global trials running in parallel

Tellier disclosed a concrete operational detail that should interest any international patient tracking clinical-trial enrollment: UCB decided six or seven years ago that every global multi-centre clinical trial for a strategic product would include Chinese, Japanese, and other Asian patients, so the company could file simultaneously in major regulatory regions.

Today, 14 global multi-centre clinical trials are running simultaneously in China under that policy. The implication for an international patient is direct: if a UCB pipeline drug is in Phase 2 or Phase 3 and the patient qualifies for the indication, there is a meaningful probability that a Chinese trial site is open and enrolling. This is structurally different from a "China-only" or "ex-China" trial design — it is a single global protocol with Chinese sites as full participants.

For a Western patient with a refractory autoimmune disease (UCB's traditional strength in neurology and immunology), this means the option of traveling to a Chinese hospital to enroll in the same trial that a patient in Boston or Berlin could enroll in. The data contributed feeds a single global NDA package. The drug, if approved, becomes available in both markets.

The end of "China for China"

Tellier's clearest framing of the strategic shift is about where innovation now originates rather than where products are sold: "We have reached a point where, particularly because of its innovations, China has now reached a level of development that is global by nature."

The old "China for China" assumption — that anything developed in China would only be sold in China, and that the rest of the world would ignore it — is what the UCB CEO is publicly rejecting. The new framing is closer to: a Chinese-discovered antibody is a candidate for the global market from day one, on the same regulatory track as a Belgian-discovered or American-discovered antibody.

This is the same logic that drove Akeso's ivonescimab to land international licensing deals, that put Mabwell's 6MW5311 on a parallel IND-clearance track, and that has made Hengrui's ASCO 2026 presentations matter to oncologists in Houston and Heidelberg. Tellier is naming a pattern that the data has been showing for two years.

What international patients should take from this

Three concrete things.

First, count Chinese sites when evaluating a Western pharma trial. If a UCB, Roche, Sanofi, or AstraZeneca pipeline drug has a global Phase 2 or Phase 3, there is a real chance the protocol includes Chinese hospital sites under the same inclusion/exclusion criteria. The fastest way to confirm: check ClinicalTrials.gov or the Chinese Clinical Trial Registry (chinadrugtrials.org.cn) for site lists. The presence of Beijing, Shanghai, or Guangzhou sites means an international patient can enroll in-country rather than traveling to a Western site.

Second, recognise that Chinese-discovered drugs now have a credible path to global launch. When a Chinese biotech signs a licensing deal with a Western major (Akeso–Summit for ivonescimab, Antengene–UCB for ATG-201, and others in 2025–2026), the asset has typically cleared enough regulatory and clinical milestones that the Western partner is willing to take on the global development cost. For international patients, this is a quality signal — the drug has been independently evaluated by a team whose business depends on the asset's eventual FDA or EMA approval.

Third, the Suzhou Industrial Park signal. UCB's new China Integrated Operation Centre is not a sales office. It is a manufacturing, distribution, and regulatory-affairs hub that takes 18–36 months to build out. Companies do not make that kind of capital commitment unless they expect the local market to be a multi-decade growth driver. For a patient asking "will the drug I get in Shanghai next year still be available in five years?" the answer from UCB's investment pattern is: yes, the supply chain is being deliberately anchored in China rather than routed through Brussels.

Where this leaves the medical-tourism framing

The inbound medical-tourism story has been, for the past 18 months on this site, framed around individual patients — a New Zealander named Stuart Lye who came for CAR-T, a Pakistani who came for the same, an Indonesian who came for stem-cell therapy. Those stories matter. They are why the site exists.

But UCB's June 26 announcement is a reminder that the macro story is moving faster than the micro stories can keep up with. China has shifted from being a place where Western drugs are sold to a place where Western CEOs publicly state that global drug discovery now depends on. For an international patient evaluating China as a treatment destination, the implication is not "you can get a Western drug cheaper here." The implication is closer to: "you may be able to get a Chinese-originated drug here that no one in the West can get yet, and you may be able to enroll in a global Western-pharma trial here that has Chinese sites."

Both directions of patient flow — into China for Chinese-discovered therapies, into Chinese sites of global trials — are now structurally normal. The 2026 NMPA approval count and the 14-trial UCB disclosure are the public data points that confirm the trend is no longer anecdotal.

What to watch in the next 12 months

Three concrete forward indicators.

1. NMPA's 2026 full-year innovative-drug approval total. If the current pace of 19 approvals in the first half holds, the 2026 total could match or exceed the 2025 record of 76. The composition matters even more than the count: if 15 of 19 are from Chinese manufacturers in the first half, what is that ratio for the full year? A rising ratio would confirm Tellier's "1 in 4 globally" framing; a falling ratio would suggest Western multinationals are catching up on their Chinese pipelines.

2. New UCB pipeline assets filing in China simultaneously with FDA. UCB has 14 global trials running in China today. The next data point to watch is whether the company's 2027 pipeline additions (specific assets not yet disclosed publicly) continue the policy of including Chinese sites in the global protocol from day one. If yes, the structural integration is durable; if no, the "1 in 4" comment is a one-time talking point rather than a strategic commitment.

3. Whether other Western pharma CEOs follow Tellier's lead with on-the-record China-framing. Tellier's interview is striking for what it does not say: there is no hedging about IP risk, regulatory uncertainty, or geopolitical exposure. If Pfizer, Novartis, Merck, or Roche CEOs make similarly direct statements in the next 6–12 months, the industry-wide recognition of the shift will be confirmed. If not, UCB may be an early mover whose framing becomes the standard only if competitors follow.

Sources: China Daily interview with UCB CEO Jean-Christophe Tellier, published June 26, 2026, syndicated via The Star (Malaysia) and Asia News Network. China Daily statistics on 2025 NMPA approvals cross-referenced with NMPA annual report (76 innovative drugs in 2025, 48 in 2024).